| Edward Monaco Iii, MD, PHD | |
|
100 N Academy Ave, Danville, PA 17822-2536 | |
| (570) 271-6437 | |
| Not Available |
| Full Name | Edward Monaco Iii |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 18 Years |
| Location | 100 N Academy Ave, Danville, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508063017 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | MD447881 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Geisinger Medical Center | Danville, PA | Hospital |
| Geisinger-bloomsburg Hospital | Bloomsburg, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Geisinger Clinic | 5395657001 | 2866 |
News Archive
Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).
When H5N1 was thought to be quiescent in 2006, in a prospective open trial, FluForecast, a software program which measures virus gene proteins, predicted high human mortality H5N1 outbreaks to come.
Harvard University professor Daniel Carpenter has made revisions to a study published in March that found prescription drugs hurried through the FDA approval process are more likely to later be linked to safety risks, but he maintains that the study's conclusions are still accurate, the Wall Street Journal reports.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to the emergence of new agents that have the potential to affect disease progression, the Alzheimer's disease drug market will more than triple, from $4.3 billion in 2009 to $13.3 billion in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
A new study sheds light on why normal prion proteins may experience age-related mutations in inherited diseases. Researchers at the Case Western Reserve University School of Medicine studied a previously discovered mutation in the prion protein in members of an extended family in Indiana who inherited the prion disease Gerstmann-Straussler-Sheinker (GSS).
› Verified 7 days ago
| Entity Name | Geisinger Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366493868 PECOS PAC ID: 5395657001 Enrollment ID: O20040130000518 |
News Archive
Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).
When H5N1 was thought to be quiescent in 2006, in a prospective open trial, FluForecast, a software program which measures virus gene proteins, predicted high human mortality H5N1 outbreaks to come.
Harvard University professor Daniel Carpenter has made revisions to a study published in March that found prescription drugs hurried through the FDA approval process are more likely to later be linked to safety risks, but he maintains that the study's conclusions are still accurate, the Wall Street Journal reports.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to the emergence of new agents that have the potential to affect disease progression, the Alzheimer's disease drug market will more than triple, from $4.3 billion in 2009 to $13.3 billion in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
A new study sheds light on why normal prion proteins may experience age-related mutations in inherited diseases. Researchers at the Case Western Reserve University School of Medicine studied a previously discovered mutation in the prion protein in members of an extended family in Indiana who inherited the prion disease Gerstmann-Straussler-Sheinker (GSS).
› Verified 7 days ago
| Entity Name | University Of Pittsburgh Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619935004 PECOS PAC ID: 8729990239 Enrollment ID: O20040308000883 |
News Archive
Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).
When H5N1 was thought to be quiescent in 2006, in a prospective open trial, FluForecast, a software program which measures virus gene proteins, predicted high human mortality H5N1 outbreaks to come.
Harvard University professor Daniel Carpenter has made revisions to a study published in March that found prescription drugs hurried through the FDA approval process are more likely to later be linked to safety risks, but he maintains that the study's conclusions are still accurate, the Wall Street Journal reports.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to the emergence of new agents that have the potential to affect disease progression, the Alzheimer's disease drug market will more than triple, from $4.3 billion in 2009 to $13.3 billion in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
A new study sheds light on why normal prion proteins may experience age-related mutations in inherited diseases. Researchers at the Case Western Reserve University School of Medicine studied a previously discovered mutation in the prion protein in members of an extended family in Indiana who inherited the prion disease Gerstmann-Straussler-Sheinker (GSS).
› Verified 7 days ago
| Entity Name | Upmc Altoona Regional Health Services, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396724217 PECOS PAC ID: 5395659312 Enrollment ID: O20040312000257 |
News Archive
Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).
When H5N1 was thought to be quiescent in 2006, in a prospective open trial, FluForecast, a software program which measures virus gene proteins, predicted high human mortality H5N1 outbreaks to come.
Harvard University professor Daniel Carpenter has made revisions to a study published in March that found prescription drugs hurried through the FDA approval process are more likely to later be linked to safety risks, but he maintains that the study's conclusions are still accurate, the Wall Street Journal reports.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to the emergence of new agents that have the potential to affect disease progression, the Alzheimer's disease drug market will more than triple, from $4.3 billion in 2009 to $13.3 billion in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
A new study sheds light on why normal prion proteins may experience age-related mutations in inherited diseases. Researchers at the Case Western Reserve University School of Medicine studied a previously discovered mutation in the prion protein in members of an extended family in Indiana who inherited the prion disease Gerstmann-Straussler-Sheinker (GSS).
› Verified 7 days ago
| Entity Name | Geisinger-hm Joint Venture Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144876137 PECOS PAC ID: 1355676370 Enrollment ID: O20190826000803 |
News Archive
Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).
When H5N1 was thought to be quiescent in 2006, in a prospective open trial, FluForecast, a software program which measures virus gene proteins, predicted high human mortality H5N1 outbreaks to come.
Harvard University professor Daniel Carpenter has made revisions to a study published in March that found prescription drugs hurried through the FDA approval process are more likely to later be linked to safety risks, but he maintains that the study's conclusions are still accurate, the Wall Street Journal reports.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to the emergence of new agents that have the potential to affect disease progression, the Alzheimer's disease drug market will more than triple, from $4.3 billion in 2009 to $13.3 billion in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
A new study sheds light on why normal prion proteins may experience age-related mutations in inherited diseases. Researchers at the Case Western Reserve University School of Medicine studied a previously discovered mutation in the prion protein in members of an extended family in Indiana who inherited the prion disease Gerstmann-Straussler-Sheinker (GSS).
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Edward Monaco Iii, MD, PHD 100 N Academy Ave, Danville, PA 17822-4903 Ph: (570) 271-6144 | Edward Monaco Iii, MD, PHD 100 N Academy Ave, Danville, PA 17822-2536 Ph: (570) 271-6437 |
News Archive
Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).
When H5N1 was thought to be quiescent in 2006, in a prospective open trial, FluForecast, a software program which measures virus gene proteins, predicted high human mortality H5N1 outbreaks to come.
Harvard University professor Daniel Carpenter has made revisions to a study published in March that found prescription drugs hurried through the FDA approval process are more likely to later be linked to safety risks, but he maintains that the study's conclusions are still accurate, the Wall Street Journal reports.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to the emergence of new agents that have the potential to affect disease progression, the Alzheimer's disease drug market will more than triple, from $4.3 billion in 2009 to $13.3 billion in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
A new study sheds light on why normal prion proteins may experience age-related mutations in inherited diseases. Researchers at the Case Western Reserve University School of Medicine studied a previously discovered mutation in the prion protein in members of an extended family in Indiana who inherited the prion disease Gerstmann-Straussler-Sheinker (GSS).
› Verified 7 days ago
Dr. Oded Goren, M.D Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6144 | |
Dr. George Rymarczuk, MD Neurological Surgery Medicare: Medicare Enrolled Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6437 Fax: 570-271-6663 | |
Isabela Marlene Tetino, PA-C Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6367 Fax: 570-271-7142 | |
Dr. Amir R. Dehdashti, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6437 Fax: 570-271-6663 | |
Dr. Aurora Seaton Cruz, MD Neurological Surgery Medicare: Medicare Enrolled Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6437 Fax: 570-271-6663 | |
Matthew Kole, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6437 Fax: 570-271-6663 | |
Ali Reza Tafreshi, Neurological Surgery Medicare: Medicare Enrolled Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6211 |